HS 10380
Alternative Names: HS-10380Latest Information Update: 03 Aug 2023
At a glance
- Originator Jiangsu Hansoh Pharmaceutical; Shanghai Hansoh Biomedical
- Developer Jiangsu Hansoh Pharmaceutical
- Class Antipsychotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
Most Recent Events
- 03 Aug 2023 Jiangsu Hansoh Pharmaceutical plans phase-I/II trial in Schizophrenia in China (PO) (NCT05964790)
- 01 Aug 2022 Phase-I clinical trials in Schizophrenia (In volunteers) in China (PO) (NCT05480592)
- 29 Jul 2022 Preclinical trials in Schizophrenia (In volunteers, In adults) in China (PO)